Biogen gains exclusive rights to Vanqua’s oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases.
Latest Ratings for BIIB
DateFirmActionFromTo Mar 2022StifelDowngradesBuyHold Mar 2022RBC CapitalUpgradesSector PerformOutperform Feb 2022Canaccord GenuityMaintainsBuy